All In Biotech

Drug Trial Radar · NCT05109091

Study of ATH434 in Participants with Multiple System Atrophy

A Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in Multiple System Atrophy

Last checked: Nov 19, 2026Latest source record: Dec 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

77

Actual

Start

Jul 1, 2022

Primary completion

Nov 28, 2024

Study completion Nov 28, 2024

Sponsor

Lead sponsor
Alterity TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the safety and efficacy of ATH434 in participants with Multiple System Atrophy

Conditions

  • Multiple System Atrophy

Interventions

  • ATH434 dose level 1Drug

    ATH434 taken BID

  • ATH434 dose level 2Drug

    ATH434 taken BID

  • PlaceboDrug

    Placebo taken BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in iron content as measured by brain MRITime frame: Change from Baseline to Week 52

Locations

23 sites in 6 countries. Site status is shown where the registry gives one.

  • University of California San Diego

    La Jolla, California

  • Rush University Medical Center

    Chicago, Illinois

  • Johns Hopkins University

    Baltimore, Maryland

  • Columbia University Irving Medical Center

    New York, New York

  • The Movement Disorder Clinic of Oklahoma

    Tulsa, Oklahoma

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • St Vincent's Hospital (Sydney)

    Darlinghurst, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • CHU de Bordeaux/Groupe Hospitalier Pellegrin

    Bordeaux, France

  • CHU de Marseille/Hôpital de la Timone

    Marseille, France

  • CHU de Toulouse/Hôpital Pierre-Paul Riquet

    Toulouse, Haute-Garonne, France

  • CHU/HU Pitié Salpêtrière

    Paris, Île-de-France Region, France

  • Policlinico di Milano

    Milan, Italy

  • Azienda Ospedaliero-Universitaria Pisana

    Pisa, Italy

  • AOU San Giovanni di Dio Ruggi d'Aragona

    Salerno, Italy

  • IRCCS Istituto Delle Scienze Neurologiche di Bologna

    Bologna, Bologna, Italy

  • New Zealand Brain Research Institute

    Christchurch, New Zealand

  • Auckland City Hospital

    Grafton, New Zealand

  • University College London

    London, England, United Kingdom

  • Newcastle University

    Newcastle upon Tyne, England, United Kingdom

  • Salford Royal Hospital

    Salford, England, United Kingdom

  • Queen Elizabeth University Hospital

    Glasgow, Scotland, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.